Hepatocellular carcinoma or interferon-based therapy history attenuates sofosbuvir/ribavirin for Japanese genotype 2 hepatitis C virus

doi:10.3748/wjg.v24.i13.1478

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 24, Issue 13

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8854)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-5) series, Tables (1-3) series.

Item

Count

PDF

380

WORD

184

HTML

4928

Figures (1-5)

248

Tables (1-3)

246

Sum=5986

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1145

Download

1723

Sum=2868

Apr 7, 2018 (publication date) through Jan 3, 2025

Times Cited of This Article

Times Cited (6)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Prospective Study

World J Gastroenterol. Apr 7, 2018; 24(13): 1478-1485
Published online Apr 7, 2018. doi: 10.3748/wjg.v24.i13.1478

Full Size Figure Download Figure

Figure 2 Flow sheet of this study (A) and virological response rates for combination therapy with sofosbuvir and ribavirin (B). The rates of sustained virological response at 12 wk after the end of treatment are shown for intention to treat and per protocol analyses. PP: Per protocol; ITT: Intention to treat; SVR12: Sustained virological response at 12 wk after the end of treatment.

Citation: Yada M, Miyazaki M, Tanaka K, Masumoto A, Motomura K. Hepatocellular carcinoma or interferon-based therapy history attenuates sofosbuvir/ribavirin for Japanese genotype 2 hepatitis C virus. World J Gastroenterol 2018; 24(13): 1478-1485
URL: https://www.wjgnet.com/1007-9327/full/v24/i13/1478.htm
DOI: https://dx.doi.org/10.3748/wjg.v24.i13.1478